molecules of the month

Vixotrigine (BIIB074)

BP, use-dependent sodium channel blocker

Ph. II oral efficacy in trigeminal neuralgia

from cell-based HTS and ligand-based opt.

ACS Med. Chem. Lett., Jul. 16, 2020

biogen / Convergence / GSK, MA / UK

Structure of Vixotrigine (BIIB074), a voltage- and use-dependent sodium channel blocker
1 min read

Vixotrigine (BIIB074) is a voltage-gated sodium channel blocker that preferentially binds to the inactivated state of the sodium channels, conferring selectivity for channels involved in pain-associated high frequency nerve signalling over normal low frequency nerve signalling (use-/state-dependence). The use-dependent activity is believed to confer a better safety window over previous generations of sodium channel inhibitors. Two Ph. III clinical trials appear to be planned for trigeminal neuralgia with estimated start dates in mid-2021.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: